197 related articles for article (PubMed ID: 34549308)
1. miR‑125a‑5p reverses epithelial‑mesenchymal transition and restores drug sensitivity by negatively regulating TAFAZZIN signaling in breast cancer.
Li D; Chen L; Zhang X; Wang Y; Huang C; Li J; He F; He W
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34549308
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA‑125a‑5p regulates liver cancer cell growth, migration and invasion and EMT by targeting HAX1.
Zha Z; Li J
Int J Mol Med; 2020 Nov; 46(5):1849-1861. PubMed ID: 33000203
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA‑125a‑5p controls the proliferation, apoptosis, migration and PTEN/MEK1/2/ERK1/2 signaling pathway in MCF‑7 breast cancer cells.
Liang Z; Pan Q; Zhang Z; Huang C; Yan Z; Zhang Y; Li J
Mol Med Rep; 2019 Nov; 20(5):4507-4514. PubMed ID: 31702027
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway.
Zhao Y; Ma K; Yang S; Zhang X; Wang F; Zhang X; Liu H; Fan Q
Int J Oncol; 2018 Aug; 53(2):644-658. PubMed ID: 29767234
[TBL] [Abstract][Full Text] [Related]
5. The downregulation of miR‑125a‑5p functions as a tumor suppressor by directly targeting MMP‑11 in osteosarcoma.
Waresijiang N; Sun J; Abuduaini R; Jiang T; Zhou W; Yuan H
Mol Med Rep; 2016 Jun; 13(6):4859-64. PubMed ID: 27081863
[TBL] [Abstract][Full Text] [Related]
6. lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR‑125a‑5p.
Liu Y; Li M; Yu H; Piao H
Int J Mol Med; 2020 Feb; 45(2):497-509. PubMed ID: 31894257
[TBL] [Abstract][Full Text] [Related]
7. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
[TBL] [Abstract][Full Text] [Related]
8. BRD7 suppresses invasion and metastasis in breast cancer by negatively regulating YB1-induced epithelial-mesenchymal transition.
Niu W; Luo Y; Zhou Y; Li M; Wu C; Duan Y; Wang H; Fan S; Li Z; Xiong W; Li X; Li G; Ren C; Li H; Zhou M
J Exp Clin Cancer Res; 2020 Feb; 39(1):30. PubMed ID: 32028981
[TBL] [Abstract][Full Text] [Related]
9. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
[TBL] [Abstract][Full Text] [Related]
10. USP37 downregulation elevates the Chemical Sensitivity of Human Breast Cancer Cells to Adriamycin.
Qin T; Cui XY; Xiu H; Huang C; Sun ZN; Xu XM; Li LH; Yue L
Int J Med Sci; 2021; 18(2):325-334. PubMed ID: 33390801
[No Abstract] [Full Text] [Related]
11. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
[TBL] [Abstract][Full Text] [Related]
13. Tumor-promoting properties of miR-8084 in breast cancer through enhancing proliferation, suppressing apoptosis and inducing epithelial-mesenchymal transition.
Gao Y; Ma H; Gao C; Lv Y; Chen X; Xu R; Sun M; Liu X; Lu X; Pei X; Li P
J Transl Med; 2018 Feb; 16(1):38. PubMed ID: 29471858
[TBL] [Abstract][Full Text] [Related]
14. Effect of miR-7 on resistance of breast cancer cells to adriamycin via regulating EGFR/PI3K signaling pathway.
Huang Q; Wu YY; Xing SJ; Yu ZW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5285-5292. PubMed ID: 31298380
[TBL] [Abstract][Full Text] [Related]
15. Downregulated miR‑130a enhances the sensitivity of acute myeloid leukemia cells to Adriamycin.
Liu H; Liu M; Zhang J; Liang Y
Mol Med Rep; 2020 Oct; 22(4):2810-2816. PubMed ID: 32945422
[TBL] [Abstract][Full Text] [Related]
16. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
Zhong S; Li W; Chen Z; Xu J; Zhao J
Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
[TBL] [Abstract][Full Text] [Related]
17. Curcumin attenuates lncRNA H19‑induced epithelial‑mesenchymal transition in tamoxifen‑resistant breast cancer cells.
Cai J; Sun H; Zheng B; Xie M; Xu C; Zhang G; Huang X; Zhuang J
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179087
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway.
Pan Y; Chen J; Tao L; Zhang K; Wang R; Chu X; Chen L
Oncotarget; 2017 May; 8(20):33144-33158. PubMed ID: 28388536
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]